Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lucid Diagnostics Inc (LUCD)

Lucid Diagnostics Inc (LUCD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 147,321
  • Shares Outstanding, K 137,683
  • Annual Sales, $ 4,350 K
  • Annual Income, $ -45,530 K
  • EBIT $ -48 M
  • EBITDA $ -46 M
  • 60-Month Beta 1.22
  • Price/Sales 33.90
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.08
  • Number of Estimates 1
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +61.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0300 +1.94%
on 11/11/25
1.2900 -18.60%
on 10/27/25
-0.1300 (-11.02%)
since 10/17/25
3-Month
0.9800 +7.14%
on 08/20/25
1.5397 -31.80%
on 09/05/25
+0.0300 (+2.94%)
since 08/18/25
52-Week
0.7501 +39.98%
on 12/26/24
1.8000 -41.67%
on 04/08/25
+0.1000 (+10.53%)
since 11/18/24

Most Recent Stories

More News
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results

Veris Health launched commercial phase of strategic partnership and relaunched development of implantable physiological monitor

LUCD : 1.0500 (-1.87%)
PAVM : 0.3800 (-1.07%)
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results

Processed 2,841 EsoGuard ® tests and recognized 3Q25 revenue of $1.2 million, ending quarter with over $47 million in proforma cash and extending runway through 2026 and well past upcoming reimbursement...

LUCD : 1.0500 (-1.87%)
PAVM : 0.3800 (-1.07%)
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025

Conference Call and Webcast at 8:30 AM Eastern Time

LUCD : 1.0500 (-1.87%)
PAVM : 0.3800 (-1.07%)
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit

NEW YORK , Oct. 15, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD)  ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and...

LUCD : 1.0500 (-1.87%)
PAVM : 0.3800 (-1.07%)
Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors

LUCD : 1.0500 (-1.87%)
PAVM : 0.3800 (-1.07%)
Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion...

LUCD : 1.0500 (-1.87%)
PAVM : 0.3800 (-1.07%)
Lucid Diagnostics Announces Closing of Public Offering of Common Stock

NEW YORK , Sept. 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company,...

LUCD : 1.0500 (-1.87%)
PAVM : 0.3800 (-1.07%)
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

NEW YORK , Sept. 10, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company,...

LUCD : 1.0500 (-1.87%)
PAVM : 0.3800 (-1.07%)
Lucid Diagnostics Announces Proposed Public Offering of Common Stock

NEW YORK , Sept. 9, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company,...

LUCD : 1.0500 (-1.87%)
PAVM : 0.3800 (-1.07%)
Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

Conference call scheduled for Monday, September 8 , at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting

LUCD : 1.0500 (-1.87%)
PAVM : 0.3800 (-1.07%)

Business Summary

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. Lucid Diagnostics Inc. is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 1.1133
2nd Resistance Point 1.0967
1st Resistance Point 1.0733
Last Price 1.0500
1st Support Level 1.0333
2nd Support Level 1.0167
3rd Support Level 0.9933

See More

52-Week High 1.8000
Fibonacci 61.8% 1.3989
Fibonacci 50% 1.2750
Fibonacci 38.2% 1.1512
Last Price 1.0500
52-Week Low 0.7501

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar